{"title":"开发用于局部治疗乳腺导管原位癌的厄洛替尼负载纳米转运体凝胶。","authors":"Bharti Mangla, Priya Mittal, Pankaj Kumar, Shamama Javed, Waquar Ahsan, Geeta Aggarwal","doi":"10.2217/nnm-2023-0260","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aims:</b> This study was aimed to formulate erlotinib (ERL)-loaded transferosomal gel (ERL@TG) intended for topical application for the treatment of ductal carcinoma <i>in situ</i>. <b>Materials & methods:</b> The optimized process involved a thin-film hydration method to generate ERL-loaded transferosomes (ERL@TFS), which was incorporated into a carbopol gel matrix to generate ERL@TG. The optimized formulation was characterized <i>in vitro</i> followed by cytotoxicity evaluation on MCF-7 breast cancer cell lines and acute toxicity and skin irritation studies was performed <i>in vivo</i>. <b>Results:</b> In a comparative assessment against plain ERL, ERL@TG displayed enhanced efficacy against MCF-7 cell lines, reflected in considerably lower IC<sub>50</sub> values with an enhanced safety profile. <b>Conclusion:</b> Optimized ERL@TG was identified as a promising avenue for addressing ductal carcinoma <i>in situ</i> breast cancer.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"855-874"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma <i>in situ</i>.\",\"authors\":\"Bharti Mangla, Priya Mittal, Pankaj Kumar, Shamama Javed, Waquar Ahsan, Geeta Aggarwal\",\"doi\":\"10.2217/nnm-2023-0260\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aims:</b> This study was aimed to formulate erlotinib (ERL)-loaded transferosomal gel (ERL@TG) intended for topical application for the treatment of ductal carcinoma <i>in situ</i>. <b>Materials & methods:</b> The optimized process involved a thin-film hydration method to generate ERL-loaded transferosomes (ERL@TFS), which was incorporated into a carbopol gel matrix to generate ERL@TG. The optimized formulation was characterized <i>in vitro</i> followed by cytotoxicity evaluation on MCF-7 breast cancer cell lines and acute toxicity and skin irritation studies was performed <i>in vivo</i>. <b>Results:</b> In a comparative assessment against plain ERL, ERL@TG displayed enhanced efficacy against MCF-7 cell lines, reflected in considerably lower IC<sub>50</sub> values with an enhanced safety profile. <b>Conclusion:</b> Optimized ERL@TG was identified as a promising avenue for addressing ductal carcinoma <i>in situ</i> breast cancer.</p>\",\"PeriodicalId\":74240,\"journal\":{\"name\":\"Nanomedicine (London, England)\",\"volume\":\" \",\"pages\":\"855-874\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nanomedicine (London, England)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/nnm-2023-0260\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/nnm-2023-0260","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/5 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma in situ.
Aims: This study was aimed to formulate erlotinib (ERL)-loaded transferosomal gel (ERL@TG) intended for topical application for the treatment of ductal carcinoma in situ. Materials & methods: The optimized process involved a thin-film hydration method to generate ERL-loaded transferosomes (ERL@TFS), which was incorporated into a carbopol gel matrix to generate ERL@TG. The optimized formulation was characterized in vitro followed by cytotoxicity evaluation on MCF-7 breast cancer cell lines and acute toxicity and skin irritation studies was performed in vivo. Results: In a comparative assessment against plain ERL, ERL@TG displayed enhanced efficacy against MCF-7 cell lines, reflected in considerably lower IC50 values with an enhanced safety profile. Conclusion: Optimized ERL@TG was identified as a promising avenue for addressing ductal carcinoma in situ breast cancer.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
